Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study. [electronic resource]
Producer: 20160519Description: 914-920 p. digitalISSN:- 1569-8041
- Aged
- Antibiotics, Antineoplastic -- adverse effects
- Antineoplastic Agents, Alkylating -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- BRCA1 Protein -- genetics
- DNA-Binding Proteins -- genetics
- Dioxoles -- adverse effects
- Disease Progression
- Disease-Free Survival
- Doxorubicin -- adverse effects
- Endonucleases -- genetics
- Female
- Humans
- Middle Aged
- Mutation
- Neoplasm Recurrence, Local
- Nuclear Proteins -- genetics
- Ovarian Neoplasms -- drug therapy
- Pharmacogenetics
- Polyethylene Glycols -- adverse effects
- Tetrahydroisoquinolines -- adverse effects
- Time Factors
- Trabectedin
- Transcription Factors -- genetics
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.